Merck
Science and technology in healthcare, life science, performance materials..
Launch date
Employees
Market cap
€265.6b
Enterprise valuation
€284.9b (Public information from Sep 2024)
Share price
$117.23
Darmstadt Hesse (HQ)
Corporate Venture Fund: M Ventures
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 48.0b | 48.7b | 59.3b | 60.1b | 64.2b | 68.5b | 72.7b |
% growth | 2 % | 1 % | 22 % | 1 % | 7 % | 7 % | 6 % |
EBITDA | 20.6b | 20.9b | 26.4b | 10.1b | 28.1b | 32.6b | 34.9b |
% EBITDA margin | 43 % | 43 % | 45 % | 17 % | 44 % | 48 % | 48 % |
Profit | 7.1b | 13.0b | 14.5b | 365m | 19.0b | 22.9b | 25.7b |
% profit margin | 15 % | 27 % | 24 % | 1 % | 30 % | 33 % | 35 % |
EV / revenue | 4.8x | 4.5x | 5.0x | 5.1x | 5.0x | 4.5x | 4.0x |
EV / EBITDA | 11.2x | 10.4x | 11.3x | 30.2x | 11.4x | 9.4x | 8.4x |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
Total Funding | - |
Recent News about Merck
EditInvestments analysisEdit
ACQUISITION by Merck Jun 2014
exited
ACQUISITION by Molecular Templates Aug 2017
ACQUISITION by Merck Dec 2014
ACQUISITION by Merck Jul 2024
ACQUISITION by Merck Dec 2021
ACQUISITION by Merck Jan 2022
ACQUISITION by Merck Jan 2021